Last weekend, Duan, 21, received his Bachelor of Science in Symbolic Systems from Stanford University. Additionally, she closed a $11 million seed investment for Clair Health. With backing from a16z Speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki, Khosla Ventures led the funding round. The company, which co-founded with Abhinav Agarwal, is developing what it claims to be the first non-invasive, continuous hormone monitor for women.
Clair Health's wearable wristband uses a stack of ten biosensors, including biomagnetic sensors that it claims are not found in any competing consumer wearable, to read physiological signals like skin temperature, heart rate variability, and electrodermal activity. These markers are then run through AI models to determine a woman's hormonal cycle rather than taking blood or puncturing skin, reports Fortune.
“Right now, to measure hormones, you either do a blood test in a lab or you pee on a stick at home,” Duan told Fortune. “Any urine test is also not looking at hormones directly—they’re looking at how your body metabolizes them.”
When compared to daily urine samples, which are the same standard as at-home ovulation strips rather than a clinical blood study, Clair's AI accurately determined a woman's menstrual cycle phase 94% of the time. There are ongoing independent third-party investigations, such as one conducted by Stanford, that will eventually present more accurate data.
Related Oura Introduces AI Model for Women’s Health
This area has been the focus of several wearable tech firms. Whoop introduced women's hormonal insights in 2025 and this spring included a blood test panel tailored to women. In February 2026, smart ring manufacturer Oura introduced a customized AI model for women's health. Additionally, Natural Cycles already uses Oura's temperature sensor to power FDA-approved birth control. However, none of it was created specifically for hormones.
“Much of wearable technology being developed is bro-tech for tech-bros,” Dr. Alex Morgan, partner at Khosla Ventures, said in a statement to Fortune. “This team has identified the larger under-addressed market of women interested in improving their health and wellness through getting insights specifically designed for women.”
The global femtech market is projected to nearly triple from $39 billion in 2024 to $97 billion by 2030, according to Fortune report.
In order to get to market more quickly, Clair plans to launch as a wellness product in November and then seek FDA approval. The company has already sold out its presale and has a waitlist of 25,000 people. Fertility clinics have sent it over 100 letters of intent. Perimenopause monitoring, hormone replacement treatment calibration, and endometriosis and PCOS diagnostics are all part of the longer-term plan.
With zero-knowledge encryption and on-device computing for women who choose not to have their health information saved in the cloud, the company is moving closer to HIPAA compliance.
